argenx Announces VYVGART SC Prefilled Syringe for Self-Injection in Chronic Inflammatory Demyelinating Polyneuropathy Authorized for Sale by Health Canada

CNW/ - argenx SE (EURONEXT: ARGX) (Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that Health Canada ...
Newswire

argenx Announces VYVGART SC Prefilled Syringe for Self-Injection in Chronic Inflammatory Demyelinating Polyneuropathy Authorized for Sale by Health Canada

VYVGART ® SC is first and only neonatal Fc receptor blocker approved to treat CIDP Authorization is based on global ADHERE study, the largest clinical trial in CIDP to date First novel, targeted ...
The Daily News

Chronic Inflammatory Demyelinating Polyneuropathy Market Report 2025 | Grifols, Kedrion Biopharma, Octapharma, AstraZeneca's Alexion, Argenx, Horizon Therapeutics, and Biogen ...

The "Chronic Inflammatory Demyelinating Polyneuropathy Market - A Global and Regional Analysis: Focus on Distribution Channel, Route of Administration, and Region - Analysis and Forecast, 2025-2035" ...
WKRG

Press Release: Riliprubart granted orphan drug designation in Japan for chronic inflammatory demyelinating polyneuropathy

Two phase 3 studies are currently underway testing riliprubart in people with CIDP as a potential first-in-class treatment Japanese Ministry of Health, Labour and Welfare decision adds to similar ...
WesternSlopeNow

Halozyme Announces argenx Received European Commission Approval for VYVGART® Subcutaneous Injection with ENHANZE® for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

SC injection of VYVGART® is available as a vial or prefilled syringe and can be administered by a patient, caregiver, or healthcare professional SAN DIEGO, June 20, 2025 /PRNewswire/ -- Halozyme ...